

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

SYH2046 TABLETS OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that SYH2046 Tablets (the “**Product**”) developed by the Group has obtained approval from the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.

The Product is a first-in-class small molecule drug with novel structure and complete independent intellectual property rights. The indication for this clinical trial approval is heart failure after acute myocardial infarction. Preclinical studies showed that the Product could significantly improve the cardiac function and reduce adverse cardiac remodeling in disease animal models, with a better safety profile.

Acute myocardial infarction refers to the reduction or complete blockage of coronary artery blood supply due to various causes, resulting in severe and prolonged acute ischemia of the corresponding myocardium, which leads to myocardial cell necrosis. Acute myocardial infarction is a major cause of heart failure. The incidence of heart failure after acute myocardial infarction ranges from 14% to 36%, and the five-year mortality rate of hospitalised patients with heart failure reaches 42.3%. Heart failure is difficult to treat with poor prognosis and high patient mortality rate, while conventional medications have unsatisfactory efficacy.

Compared with conventional heart failure drugs, the Product features a completely new mechanism of action. It is expected to actively promote tissue repair in the early stage of myocardial injury by improving the metabolism of cardiac cells and thereby restore cardiac function after myocardial infarction, providing a promising clinical development value.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 11 April 2025

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.